Acacia Clinics and Vagus Nerve Society Conduct Study Using electroCore’s gammaCore Sapphire for Adjunctive Treatment of Symptoms Associated with Post-Traumatic Stress Disorder (“PTSD”)

Core Insights - electroCore, Inc. has announced a new research initiative in collaboration with Acacia Clinics and the Vagus Nerve Society to investigate the use of gammaCore™ Sapphire, a non-invasive vagus nerve stimulator (nVNS), as an adjunctive treatment for PTSD symptoms [1][2] Study Details - The study titled "Non-Invasive Vagus Nerve Stimulation (nVNS) for Adjunctive Treatment of Symptoms Associated with Post-Traumatic Stress Disorder" will be led by Danielle DeSouza MSc, PhD, and aims to assess the safety and effectiveness of gammaCore Sapphire [2] - The primary safety measure will focus on significant adverse events (SAEs) related to nVNS treatment, while the primary efficacy outcome will be the change in the Clinician-Administered PTSD Scale (CAPS-5) total score after a 12-week treatment period [2] - The study will enroll up to 40 subjects aged 18 to 70 diagnosed with PTSD and is expected to last for 10 months [3] Background Information - Acacia Clinics is recognized for its expertise in precision neuromodulation and advanced mental health services, founded in 2018 by Dr. David Carreon and Dr. Nathan Meng [4] - electroCore, Inc. focuses on improving health through innovative non-invasive bioelectronic technologies, with products like gammaCore® and Quell® targeting chronic pain syndromes [5]